Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029989 | 0.88 | SLC7A5 (0.33) | SLC1A1 | |
| SCHEMBL1679518 | 0.88 | SLC7A5 (0.33) | SLC1A1 | |
| SCHEMBL1373431 | 0.88 | PTGS1 (0.46) | SLC1A1PTGS1SLC7A11 | |
| SCHEMBL2150325 | 0.86 | ALOX15 (0.31) | SLC1A1 | |
| Hydrochloric Acid SCHEMBL7629423 | 0.86 | SLC1A1 (0.30) | SLC1A1 | |
| SCHEMBL17423639 | 0.86 | SLC7A5 (0.32) | SLC1A1 | |
| SCHEMBL10855524 | 0.86 | SLC1A1 (0.39) | SLC1A1PTGS1SLC7A11USP2SLCO1B1 | |
| SCHEMBL174379 | 0.86 | — | — | |
| SCHEMBL4260594 | 0.86 | — | — | |
| SCHEMBL678279 | 0.85 | ALDH1A1 (0.41) | SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385050-A1 | A process for preparing a substituted oxazole | Schering Corporation (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2385051-A1 | Process for making a substituted oxazole | Schering Corporation (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7985860-B2 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | SCHERING CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2069284-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 2-(QUINOLIN-5-YL)-4,5 DISUBSTITUTED-AZOLE DERIVATIVES | SCHERING CORPORATION (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008021235-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 2-(QUINOLIN-5-YL)-4,5 DISUBSTITUTED-AZOLE DERIVATIVES | SCHERING CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | PDE4B, PDE4A, PDE3B | SLC1A1 4153/4885PTGS1 588/4885SLC7A11 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.